Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on X:
“New Online JTO and JTO CRR RTK fusion-mediated resistance to EGFR-TKI in EGFR-mutated NSCLC: a multi-center analysis.
ALK (43%) and RET (36%) are most common.
EGFR-RTK dual inhibition has an ORR 24% and DCR 80% with manageable toxicities.”
Authors: Yang Xia, Kaiwen Wang, Jing Zhao, Zhaohui Arter, Yongchang Zhang, Jiaqi Zhou, Yuefei Lu, Liang Zeng, Robyn Du, Jennifer A. Owens, Yasir Y. Elamin, Carl M. Gay, Ferdinandos Skoulidis, Anne S. Tsao, Charles Lu, Tina Cascone, Don L. Gibbons, Jianjun Zhang, Olivia Chen, Kevin KS. Mok, Misako Nagasaka, Wen Li, John V. Heymach, Sai-Hong Ignatius Ou, Molly Li, Xiuning Le
